The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy
NCT06597539 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2024-12-11
Summary
This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for advanced hepatobiliary malignancies.
Conditions
- Hepatobiliary Malignancy
Sponsors & Collaborators
-
Ruijin Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-11-09
- Primary Completion
- 2026-06-30
- Completion
- 2027-07-31
Countries
- China
Study Locations
More Related Trials
-
[68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Modeling.
NCT06999837 ·Status: RECRUITING ·Phase: NA
-
68Ga-grazytracer PET/CT of Tumor Responses to Immunotherapy
NCT05000372 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
NCT06597526 ·Status: RECRUITING
-
68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
NCT05637034 ·Status: UNKNOWN ·Phase: NA
-
Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma
NCT05006326 ·Status: UNKNOWN ·Phase: NA
-
68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer.
NCT06608160 ·Status: RECRUITING
-
68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer
NCT04831541 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
The Function of PET Molecular Imaging Targeting Fibroblast Activation Protein in the Hepatobiliary Malignancies
NCT05264688 ·Status: UNKNOWN
-
MPDL3280A-imaging-IST-UMCG
NCT02453984 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
68Ga-MY6349 PET/CT in Solid Tumors
NCT07046702 ·Status: RECRUITING
-
Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma
NCT05681234 ·Status: COMPLETED ·Phase: NA
-
FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination Therapy
NCT05662488 ·Status: UNKNOWN
-
The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma
NCT06863441 ·Status: NOT_YET_RECRUITING
-
68Ga-labeled NY105 PET Imaging in Patients
NCT05691881 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma
NCT03636607 ·Status: WITHDRAWN ·Phase: NA
-
68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study
NCT06688188 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Energy CT in Imaging and Diagnosis of Gastric Cancer
NCT06869694 ·Status: RECRUITING
-
Dual Integrin αvβ3 and GRPR Targeting PET Imaging in Breast Cancer Patients
NCT02749019 ·Status: UNKNOWN ·Phase: PHASE1
-
Comaprison of 68Ga-FAP-2286 and 18F-FDG PET/CT in Patients With Various Types of Cancer
NCT05392205 ·Status: COMPLETED ·Phase: NA
-
Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases
NCT06690736 ·Status: RECRUITING ·Phase: NA
-
A Study to Evaluate the Diagnostic Efficacy of 68Ga- MY6349 PET/CT in Patients With Tumours
NCT06770478 ·Status: RECRUITING ·Phase: NA
-
68Ga-ICAM-1pep PET/CT in Cancer Patients
NCT04596670 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Trop2-targeted immunoPET Imaging of Solid Tumors
NCT06851663 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors
NCT06188468 ·Status: COMPLETED ·Phase: NA
-
Comparing 68Ga-CTR-FAPI and 18F-FDG PET/ CT in Cancer Detection
NCT06945432 ·Status: COMPLETED